This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of tyrosine with cysteine at codon 1711 of the RYR1 protein, p.(Tyr1711Cys). The maximum allele frequency for this variant among the six major gnomAD populations is AFR: 0.000125, a frequency consistent with pathogenicity for MHS. This variant has been reported in two unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, both of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Supporting (PMID:25735680, New Zealand MH Investigation Unit). This variant segregates with MHS in five individuals, PP1_Supporting (New Zealand MH Investigation Unit). Functional studies in HEK293 cells show an increased sensitivity to RYR1 agonists, PS3_Moderate (PMID:36208971). This variant does not reside in a hotspot for pathogenic variants that contribute to MHS. A REVEL score of 0.805 supports neither a pathogenic nor a benign status for this variant. This variant has been classified as a Variant of Unknown Significance. PS3_Moderate, PS4_Supporting, PP1_Supporting.